DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease – a multicentre RCT

BACKGROUND: Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while the glutamate antagonist memantine has been widely prescribed, often in the later...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Jones, Rob, Sheehan, Bart, Phillips, Patrick, Juszczak, Ed, Adams, Jessica, Baldwin, Ashley, Ballard, Clive, Banerjee, Sube, Barber, Bob, Bentham, Peter, Brown, Richard, Burns, Alistair, Dening, Tom, Findlay, David, Gray, Richard, Griffin, Mary, Holmes, Clive, Hughes, Alan, Jacoby, Robin, Johnson, Tony, Jones, Roy, Knapp, Martin, Lindesay, James, McKeith, Ian, McShane, Rupert, Macharouthu, Ajay, O'Brien, John, Onions, Caroline, Passmore, Peter, Raftery, James, Ritchie, Craig, Howard, Rob
Materialtyp: Artigo
Språk:Inglês
Publicerad: BioMed Central 2009
Ämnen:
Study Protocol
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2723100/
https://ncbi.nlm.nih.gov/pubmed/19630974
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1745-6215-10-57
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk